NeuroBo Pharmaceuticals, Inc. (NRBO)
NASDAQ: NRBO · IEX Real-Time Price · USD
4.425
+0.095 (2.19%)
At close: Jul 23, 2024, 2:41 PM
4.200
-0.225 (-5.08%)
After-hours: Jul 23, 2024, 6:43 PM EDT

NeuroBo Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2014
Selling, General & Admin
6.826.738.648.757.852.7
Upgrade
Research & Development
13.439.162.786.554.535.32
Upgrade
Other Operating Expenses
008.21017.3412.15
Upgrade
Operating Expenses
20.2515.8919.6315.329.7220.18
Upgrade
Operating Income
-20.25-15.89-19.63-15.3-29.72-20.18
Upgrade
Interest Expense / Income
002.19000.02
Upgrade
Other Expense / Income
-3.67-3.42-7.85-0.01-0.041.11
Upgrade
Pretax Income
-16.58-12.47-13.97-15.28-29.68-21.31
Upgrade
Net Income
-16.58-12.47-13.97-15.28-29.68-21.31
Upgrade
Shares Outstanding (Basic)
550000
Upgrade
Shares Outstanding (Diluted)
550000
Upgrade
Shares Change
0.60%1476.33%233.62%42.72%210.43%22.88%
Upgrade
EPS (Basic)
-3.22-2.46-43.42-158.48-439.24-979.30
Upgrade
EPS (Diluted)
-3.22-2.46-43.42-158.48-439.24-979.30
Upgrade
Free Cash Flow
-14.75-10.85-11.7-15.14-10.77-7.25
Upgrade
Free Cash Flow Per Share
-2.90-2.14-36.38-156.98-159.37-333.24
Upgrade
EBITDA
-16.57-12.46-11.75-15.21-29.61-21.27
Upgrade
Depreciation & Amortization
0.010.010.030.070.070.02
Upgrade
EBIT
-16.58-12.47-11.78-15.28-29.68-21.29
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).